Opportunity Information: Apply for PA 09 119
Apply for PA 09 119
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Phased Innovation Award Program for AIDS Vaccine Research (R21/R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy, Immunology and Transplantation Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Jun 18, 2010 and posted on Mar 6, 2009.
- Applicants must submit their applications by Jan 7, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Private institutions of higher education Small businesses For profit organizations other than small businesses City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments Public and State controlled institutions of higher education State governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Phased Innovation Award Program for AIDS Vaccine Research (R21/R33) is a National Institutes of Health (NIH) funding opportunity run through the National Institute of Allergy and Infectious Diseases (NIAID) that aims to accelerate new ideas in prophylactic HIV/AIDS vaccine research. The program is designed for projects that are genuinely innovative and novel, including concepts that may be considered high risk but could produce high impact outcomes. The central expectation is that proposed studies will have clear potential to advance how HIV vaccines are designed, improved, or evaluated on the path toward an effective preventive vaccine. The announcement is broad in scientific scope, welcoming essentially any line of investigation that can contribute to prophylactic HIV vaccine development, but it draws a firm boundary around one activity: clinical trials are not supported under this initiative.
A key feature of this opportunity is its phased structure using the NIH Phased Innovation Award mechanism, combining an R21 exploratory phase with a potential transition to an R33 developmental phase. The first phase (R21) is meant for milestone-driven exploratory or feasibility work and lasts up to two years. This is where applicants are expected to generate proof-of-concept data, validate a new approach, or demonstrate technical feasibility in a way that would justify larger-scale development. If the project meets the predefined scientific milestones established for the R21, it may be considered for rapid transition to the second phase (R33), which supports expanded development activities for an additional two to three years. The transition is not automatic; after the initial two-year period, NIAID evaluates whether the R21 milestones were completed, and only those projects that satisfy the milestones are eligible to move forward for R33 consideration. In practical terms, applicants need to think from the start about a credible set of measurable milestones and a logical progression from early feasibility to more robust development work.
From an administrative standpoint, this is a discretionary grant opportunity under NIH, tied to CFDA program areas 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research). The opportunity does not require cost sharing or matching. The listed award ceiling is $200,000, signaling that the funding level is geared toward early-stage, proof-of-concept innovation rather than large, trial-scale efforts. The opportunity was originally posted March 6, 2009, with key dates indicating it is now archived (archive date February 7, 2011). The funding opportunity number is PA-09-119, and the official title is "Phased Innovation Award Program for AIDS Vaccine Research (R21/R33)."
Eligibility is intentionally expansive and includes many organization types across academic, nonprofit, for-profit, and government sectors. Eligible applicants include private and public institutions of higher education, nonprofits (including 501(c)(3) organizations as well as certain nonprofits without 501(c)(3) status), small businesses, and other for-profit organizations. Government entities at multiple levels may apply, including city/township, county, state, special district governments, public housing authorities/Indian housing authorities, independent school districts, and U.S. territories or possessions. The eligibility list also explicitly includes a range of mission-focused and underserved-serving institutions and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, and Tribally Controlled Colleges and Universities (TCCUs). Tribal governments and tribal organizations are included, and the announcement also allows participation by non-U.S. entities (foreign organizations) and regional organizations, as well as eligible federal agencies. Faith-based and community-based organizations are also mentioned as eligible.
Overall, the opportunity is best understood as a structured on-ramp for inventive HIV vaccine concepts that need early support to prove feasibility, with a built-in pathway to continue into a more developed stage if the initial milestones are met. It emphasizes forward-looking vaccine science and measurable progress while deliberately excluding clinical trials, keeping the program focused on discovery, design, preclinical evaluation, and other preparatory research that could meaningfully strengthen the HIV prophylactic vaccine pipeline. For the full archived announcement and any detailed requirements that were in effect at the time (such as application formatting, specific budget rules for the phases, and milestone expectations), the official NIH guide notice is available at http://grants.nih.gov/grants/guide/pa-files/PA-09-119.html.
Frequently Asked Questions (FAQs)
What is the Phased Innovation Award Program for AIDS Vaccine Research (R21/R33)?
It is an NIH funding opportunity run through the National Institute of Allergy and Infectious Diseases (NIAID) designed to accelerate genuinely innovative and novel ideas in prophylactic HIV/AIDS vaccine research. The program supports early, milestone-driven work that can move from an exploratory phase (R21) into a development phase (R33) if predefined milestones are met.
Which NIH institute runs this opportunity?
The opportunity is run through NIAID (National Institute of Allergy and Infectious Diseases) within the National Institutes of Health (NIH).
What is the main goal of this program?
The central expectation is that proposed studies will have clear potential to advance how HIV vaccines are designed, improved, or evaluated on the path toward an effective preventive (prophylactic) HIV vaccine.
What kinds of projects does the program encourage?
The program is intended for projects that are genuinely innovative and novel, including concepts that may be considered high risk but could produce high impact outcomes, as long as they can contribute to prophylactic HIV vaccine development.
How broad is the scientific scope?
The announcement is broad in scientific scope and welcomes essentially any line of investigation that can contribute to prophylactic HIV vaccine development, while maintaining a firm boundary that clinical trials are not supported.
Are clinical trials allowed under this funding opportunity?
No. Clinical trials are explicitly not supported under this initiative.
What does "phased" mean in the R21/R33 mechanism?
This opportunity uses the NIH Phased Innovation Award mechanism. It combines an R21 exploratory phase (focused on feasibility and proof-of-concept) with a potential transition to an R33 development phase (focused on expanded development) if the R21 phase meets predefined milestones.
What is the purpose of the R21 phase?
The R21 phase is meant for milestone-driven exploratory or feasibility work. Applicants are expected to generate proof-of-concept data, validate a new approach, or demonstrate technical feasibility in a way that would justify larger-scale development.
How long can the R21 phase last?
Up to two years.
What is the purpose of the R33 phase?
The R33 phase supports expanded development activities after successful completion of R21 milestones, allowing projects to build on validated approaches and move toward more robust development work relevant to prophylactic HIV vaccine advancement.
How long can the R33 phase last?
An additional two to three years following the R21 phase, if the project transitions.
Is the transition from R21 to R33 automatic?
No. Transition is not automatic. After the initial two-year period, NIAID evaluates whether the R21 milestones were completed. Only projects that satisfy the milestones are eligible for R33 consideration.
What is expected regarding milestones?
Applicants are expected to define a credible set of measurable scientific milestones and propose a logical progression from early feasibility (R21) to more robust development work (R33). Meeting the R21 milestones is required to be considered for transition to R33.
What is the award ceiling listed for this opportunity?
The listed award ceiling is $200,000, indicating the funding level is geared toward early-stage, proof-of-concept innovation rather than large, trial-scale efforts.
Does this opportunity require cost sharing or matching funds?
No. The opportunity does not require cost sharing or matching.
What type of grant opportunity is this?
It is a discretionary grant opportunity under NIH using the phased R21/R33 mechanism.
What are the CFDA program areas associated with this opportunity?
This opportunity is tied to CFDA program areas 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research).
What is the funding opportunity number and official title?
The funding opportunity number is PA-09-119, and the official title is "Phased Innovation Award Program for AIDS Vaccine Research (R21/R33)."
When was the opportunity posted, and what is its current status?
It was originally posted on March 6, 2009. Key dates indicate the opportunity is archived, with an archive date of February 7, 2011.
Who is eligible to apply?
Eligibility is expansive and includes many organization types across academic, nonprofit, for-profit, and government sectors, as well as certain mission-focused and underserved-serving institutions and organizations.
Are institutions of higher education eligible?
Yes. Both private and public institutions of higher education are eligible.
Are nonprofit organizations eligible?
Yes. Eligible applicants include nonprofits, including 501(c)(3) organizations and certain nonprofits without 501(c)(3) status.
Are for-profit organizations and small businesses eligible?
Yes. Small businesses and other for-profit organizations are included as eligible applicants.
Can government entities apply, and if so, which types?
Yes. Government entities at multiple levels may apply, including city/township governments, county governments, state governments, special district governments, public housing authorities/Indian housing authorities, independent school districts, and U.S. territories or possessions.
Are tribal governments and tribal organizations eligible?
Yes. Tribal governments and tribal organizations are included in the eligibility list.
Are HBCUs and other designated serving institutions eligible?
Yes. The eligibility list explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based and community-based organizations eligible?
Yes. Faith-based and community-based organizations are mentioned as eligible.
Are foreign (non-U.S.) organizations eligible?
Yes. The announcement allows participation by non-U.S. entities (foreign organizations) and regional organizations.
Are federal agencies eligible to apply?
Yes. Eligible federal agencies are included in the eligibility list.
What kinds of activities does this program focus on if clinical trials are excluded?
The program emphasizes discovery, design, preclinical evaluation, and other preparatory research that could meaningfully strengthen the prophylactic HIV vaccine pipeline, while deliberately excluding clinical trials.
Where can someone find the official archived announcement?
The official NIH guide notice for the archived announcement is available at http://grants.nih.gov/grants/guide/pa-files/PA-09-119.html.
Browse more opportunities from the same category: Health
Next opportunity: Pesticide Regulatory Education Program (PREP) Request for Applications (RFA).
Previous opportunity: Biophotonics
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 119
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 119) also looked into and applied for these:
| Funding Opportunity |
|---|
| Public Health Traineeship Apply for HRSA 09 201 Funding Number: HRSA 09 201 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Novel Interventions for Neurodevelopmental Disorders (R34) Apply for RFA MH 09 160 Funding Number: RFA MH 09 160 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Novel Interventions for Neurodevelopmental Disorders (R21/R33) Apply for RFA MH 09 161 Funding Number: RFA MH 09 161 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| International Collaborations in Infectious Disease Research (ICIDR) (U01) Apply for RFA AI 09 010 Funding Number: RFA AI 09 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Addressing Asthma from a Public Health Perspective Apply for CDC RFA EH09 901 Funding Number: CDC RFA EH09 901 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $950,000 |
| 2009 FPH Region 2 (Virgin Islands) Apply for PA FPH 09 002 Funding Number: PA FPH 09 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $853,000 |
| Prematurity and Respiratory Outcomes Program (PROP) (U01) Apply for RFA HL 10 007 Funding Number: RFA HL 10 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Sudden Unexpected Infant Death Case Registry A Pilot Study Apply for CDC RFA DP09 904 Funding Number: CDC RFA DP09 904 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $130,000 |
| SPRANS Cooperative Agreement Programs Health Insurance Financing for Children with Special Health Apply for HRSA 09 137 Funding Number: HRSA 09 137 Agency: Health Resources and Services Administration Category: Health Funding Amount: $550,000 |
| Capacity Building Assistance (CBA) to Improve the Delivery and Effectiveness of Human Immunodeficiency Virus (HIV) Prevention Services for High Risk and/or Racial/Ethnic Minority Populations Apply for CDC RFA PS09 906 Funding Number: CDC RFA PS09 906 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,462,500 |
| Department of Defense HIV/AIDS Prevention, Care and Treatment Program Apply for DHAPPBAA09 002 Funding Number: DHAPPBAA09 002 Agency: Naval Supply Systems Command Category: Health Funding Amount: Case Dependent |
| Alcohol Research Resource Awards (R24) Apply for PAR 09 128 Funding Number: PAR 09 128 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Solicitation of Assays for High Throughput Screening (HTS) in the Molecular Libraries Probe Production Centers Network (MLPCN) (R03) Apply for PAR 09 129 Funding Number: PAR 09 129 Agency: National Institutes of Health Category: Health Funding Amount: $25,000 |
| Exploratory Investigations in Food Allergy (R21) Apply for RFA AI 09 011 Funding Number: RFA AI 09 011 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Dental Reimbursement Program Apply for HRSA 09 133 Funding Number: HRSA 09 133 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Telehealth Resource Center Grant Program Apply for HRSA 09 195 Funding Number: HRSA 09 195 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Statewide Consumer Network Grant Apply for SM 09 014 Funding Number: SM 09 014 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $70,000 |
| Mental Health Dissertation Research Grant to Increase Diversity (R36) Apply for PAR 09 132 Funding Number: PAR 09 132 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Support for Strengthening and Expanding Comprehensive HIV and AIDS Prevention Programs in the Republic of South Africa under PEPFAR Apply for CDC RFA PS09 939 Funding Number: CDC RFA PS09 939 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $4,810,000 |
| Support for Strengthening and Expanding HIV and AIDS Peer Education Prevention Programs in the Republic of South Africa under PEPFAR Apply for CDC RFA PS09 940 Funding Number: CDC RFA PS09 940 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 119", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.